The content on this site is intended for healthcare professionals only
Dr André-Guy Martin speaks to ecancer at EMUC 2019 in Vienna about an improved regimen of hormone therapy.
He outlines a recent study which showed little difference in overall survival if you used a long term hormone therapy regimen.
Dr Martin suggests a shorter regimen for those patients who do not tolerate the therapy particularly well.
Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC
Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity
Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
